-
Mashup Score: 1J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer - MedCity News - 2 day(s) ago
Enlaza Therapeutics’ drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies.
Source: medcitynews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
One irony of personalized or precision medicine (PM) is that it aims, against the advice of Hippocrates and Osler, to treat the disease, not the patient.
Source: medcitynews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4Otsuka Launches New Company to Commercialize Rejoyn, the First Digital Therapeutic for Depression - MedCity News - 3 day(s) ago
Otsuka Pharmaceutical is launching a subsidiary that will commercialize its digital therapeutic Rejoyn — as well as other digital therapeutics and connected health products down the line. Last month, Rejoyn became the first FDA-cleared digital therapeutic for patients with depression.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4Otsuka Launches New Company to Commercialize Rejoyn, the First Digital Therapeutic for Depression - MedCity News - 3 day(s) ago
Otsuka Pharmaceutical is launching a subsidiary that will commercialize its digital therapeutic Rejoyn — as well as other digital therapeutics and connected health products down the line. Last month, Rejoyn became the first FDA-cleared digital therapeutic for patients with depression.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Glen Tullman Has ‘No Interest’ In Selling Transcarent, But IPO Is a Possibility - MedCity News - 3 day(s) ago
Transcarent recently announced that it raised $126 million in Series D funding led by General Catalyst and 7wireVentures. When asked what his exit strategy is, CEO Glen Tullman said he does not want to sell Transcarent, but sees an initial public offering as an option.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1
Balancing the promise of personalized medicine with proper payment accuracy
Source: medcitynews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1INVEST 2024 - 3 day(s) ago
Join us to hear from innovative investors and entrepreneurs offering novel approaches to solve some of healthcare’s greatest challenges.
Source: www.eventbrite.comCategories: General Medicine News, General NewsTweet-
The INVEST 2024 Agenda is full of insights for healthcare professionals. Plus, we’re the industry's premier networking, uniting active investors with corporate business development executives to facilitate investment opportunities. Save $700 now. https://t.co/tujwz4IPNy #mcINVEST https://t.co/s6ZzpyF95l
-
-
Mashup Score: 5Research Shows Generative AI In The EHR Can Work Well, But Only With Human Oversight - MedCity News - 4 day(s) ago
Mass General Brigham researchers conducted a study to learn more about the efficacy of large language models when used to draft responses to patient messages in the EHR. The results showed that these AI tools can do a good job at reducing physicians’ workloads and improving patient education — but also that these tools have limitations that require human oversight.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1FDA Grants First-Ever Approval to an RNA-Based Diagnostic for Colorectal Cancer - MedCity News - 4 day(s) ago
Geneoscopy received approval for its noninvasive colorectal cancer screening test, which the FDA designated as a breakthrough device. This marks only the second time the FDA has issued an approval for a molecular diagnostic test for colorectal cancer — and the first time the agency has done so for a colorectal cancer test that uses RNA.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6
More than a third of employers are integrating accountable care into their health benefits, according to a new report from the Milken Institute. However, there are several barriers.
Source: medcitynews.comCategories: General Medicine News, General NewsTweet
“This is not just another ADC,” Enlaza CEO Sergio Duron said. “This is a different strategy to approach what is a very, very hot field right now where everyone is innovating” https://t.co/c2vZ8NK8KU #cancer #ADC #startup #covalency